Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-XL by engaging a single-residue discrepancy
Open Access
- 17 February 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Abstract
Overexpressed pro-survival B-cell lymphoma-2 (BCL-2) family proteins BCL-2 and BCL-XL can render tumor cells malignant. Leukemia drug venetoclax is currently the only approved selective BCL-2 inhibitor. However, its application has led to an emergence of resistant mutations, calling for drugs with an innovative mechanism of action. Herein we present cyclic peptides (CPs) with nanomolar-level binding affinities to BCL-2 or BCL-XL, and further reveal the structural and functional mechanisms of how these CPs target two proteins in a fashion that is remarkably different from traditional small-molecule inhibitors. In addition, these CPs can bind to the venetoclax-resistant clinical BCL-2 mutants with similar affinities as to the wild-type protein. Furthermore, we identify a single-residue discrepancy between BCL-2 D111 and BCL-XL A104 as a molecular “switch” that can differently engage CPs. Our study suggests that CPs may inhibit BCL-2 or BCL-XL by delicately modulating protein-protein interactions, potentially benefiting the development of next-generation therapeutics.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2021JQ30)
This publication has 81 references indexed in Scilit:
- Future directions for peptide therapeutics developmentDrug Discovery Today, 2013
- Structure-guided design of a selective BCL-XL inhibitorNature Chemical Biology, 2013
- A stapled BIM peptide overcomes apoptotic resistance in hematologic cancersJournal of Clinical Investigation, 2012
- Structural Basis of Bcl‐xL Recognition by a BH3‐Mimetic α/β‐Peptide Generated by Sequence‐Based DesignChemBioChem, 2011
- Mutation to Bax beyond the BH3 Domain Disrupts Interactions with Pro-survival Proteins and Promotes ApoptosisJournal of Biological Chemistry, 2011
- Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAXCell Research, 2010
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995